In a Phase 2 trial in people with metabolic dysfunction-associated steatohepatitis (MASH, a serious fatty liver disease), a majority of participants on higher doses had their liver disease resolve, far more than on placebo, along with meaningful improvement in liver scarring (fibrosis)
If I want to be able to push myself harder and faster, I don't want my heart to explode, she says
10.1007/s00125-012-2582-5
Most plans use a gradual dose escalation to help your body adjust and minimize side effects
even small, sustained declines in prevalence translate into millions fewer people living with diabetes, heart disease, sleep apnea, and painful joint disease and billions saved in medical costs over time